Before resource-intensive EAE models or clinical trials are initiated, it is critical to assess whether the well-documented safety, legal, and logistical challenges of PSYs would render them non-viable for the unique MS patient population, even if efficacy were eventually proven
Human research is limited, though animal data is robust and consistent across multiple models
Observations indicating a parallel, opposing influence of Nrf2 on the transcriptional upregulation of pro-inflammatory genes suggest that targeted pharmacological activation of the Nrf2 pathway could help in the controlled reduction of oxidative stress (Kobayashi et al
Mult Scler
published in the Journal of Applied Physiology confirmed that BPC-157 significantly accelerated outgrowth of Achilles tendon explants, markedly increased in vitro tendon fibroblast migration in a dose-dependent manner, and substantially increased fibroblast survival under HO-induced oxidative stress establishing a three-part cellular mechanism (outgrowth, migration, survival) that distinguishes BPC-157s tendon repair profile from direct mitogenic agents
